ORIGINAL ARTICLE

INTERNATIONAL JOURNAL OF EXPERIMENTAL AND BIOMEDICAL RESEARCH

Published by Pharma Springs Publication Journal Home Page: https://pharmasprings.com/ijebr

Formulation and Evaluation of Almotriptan Hydrobromide Pellets

Syed Afzal Hussain*[1], Hari Kumar C[2], Pradeep Kumar M[1], Satrasala Neelima[2]

[1]Department of Pharmaceutical Technology, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (Village), Sidhout (Mandal), Kadapa (Dist) - 516247, Andhra Pradesh, India
[2]Department of Pharmacology, Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (V), Sidhout (M), YSR Kadapa - 516 247, Andhra Pradesh, India

Article History:

Received on: 25 Jul 2022
Revised on: 14 Aug 2022
Accepted on: 15 Aug 2022

Keywords:

Almotriptan,
Controlled Release,
Dissolution Profile,
In-vitro Drug Release,
Stability Studies

ABSTRACT

An objective of the present research was to establish as well as analyze Almotriptan hydrobromide pellets. Almotriptan hydrobromide rapid onset but also controlled drug release pellets have been able to prepare through solution's/suspension layer-based technique through using croscarmellose but also povidone through former case as well as 3 different polymeric materials hydroxypropyl methylcellulose k 100, Ethyl cellulose and Eudragit RS 100 just like price trying to control polymer through 4 distinct assists ratio such as 1:0.5, 1:1, 1:1.5 as well as 1:2 to accomplish preferred discharge through later case. Evaluation has been conducted according to the pharmacopoeia norms along with opioid components suitability, percent yield, distribution of particle size, drug content evaluation as well as in-vitro release survey. One of the best results have been obtained to use the Almotriptan as well as Eudragit RS 100 through 1:2 ratios. One wide selections like release of drug pattern might be attained through variability like polymeric materials ratio analysis which has been optimized to suit a target release profile. In comparison of in-vitro release studies for various controlled drug release preparations, F12 liberates 98.54% like opioid just at end like 12^{th} hour and also was regarded as greatest preparation.

*Corresponding Author

Name: Syed Afzal Hussain
Phone: +91 9849347272
Email: syedafzal19973@gmail.com

eISSN: 2583-5254 pISSN:

DOI: https://doi.org/10.26452/ijebr.v1i3.384

Production and Hosted by

Pharmasprings.com

INTRODUCTION

Almotriptan, a triptan medicine unearthed but also evolved through almirall again for diagnosis like massive severe headache. This has been patented since 1992 as well as sanctioned for healthcare use from 2000. Almotriptan was approved to treat the acute migraine process like severe headache attacks with and without aura. Almotriptan seems to be the only triptan sanctioned in Unites States for diagnosis of migraine through adolescent from 12 to 17 year old [1]. As with other triptans, almotriptan should never be used in patients with such a history, symptoms or signs like ischaemic heart illness (myocardial infarction, angina pectoris, documented silent ischaemia, Prinzmetal's angina) but rather drastic high blood pressure as well as uncontained subtle as well as modest high blood pressure. Other contraindicated in patients were also earlier cerebral vascular accident (CVA)but rather transient ischaemic attack (TIA), peripheral vascular disease, severe liver impairment, concurrent administration like ergotamine, ergotamine derivatives (including methysergide) or other 5-HT1 B/D agonists [2].

Like all triptans, almotriptan seems to have a greater but also particular fondness just that 5-HT 1B/1D receptors. Directly binds of an opioid to a recep-

tor results in vascular constriction of craniofacial (brain) capillaries and therefore impacts a redistribution like blood to flow. Almotriptan greatly increases cerebral blood flow but also reduces the blood circulation via extracerebral coronal vessels. Although it impacts craniofacial capillaries one uniform standard mg dosage like almotriptan has had no significant clinical impact on blood pressure but rather pulse rate both in youthful but also old aged volunteers. Increasing doses, it seems to slightly increase hypertension and not further than clinical significance [3].

MATERIALS AND METHODOLOGY

Materials Used

Almotriptan Hydrobromide was a gift sample from Orchid Pvt Ltd, Chennai. Hydroxy Propyl Methyl Cellulose, Eudragit RS 100, Ethylcellulose, Acetone, Titanium Dioxide, Isopropyl Alcohol, Ethanol, PVP K-30 to be actually bought from Sisco Research Laboratories Pvt. Ltd, Mumbai.

Methodology

Drug-Excipients Compatibility Studies by Using FTIR

Prior to the event of a solid dosage form preformulation research has been carried around.

IR spectroscopy research untruths further in the subjective identifying of substances in either pure state or even in combined effect with polymeric materials but also components as well as functions as just a device through organization like chemical interplay [4].

FT-IR spectrum have been documented with such a Thermo Nicolet Japan, within range 450-4000 cm^{-1} using just a resolution of 4 cm^{-1} as well as 16 scans.

Serial dilution with KBr powder, as well as tried to press to acquire self-supporting discs biological fluids compositions have been evaluated to shape a thin fluid film among 2 KBr discs.

Formulation of Pellets

Seal Coating

Non-pariel seeds (sugar pellets) (#22/#24) have been acquired through the Aadhya Biotech Pvt Ltd.

Despite high solubilization, a fructose spheroidal instantly get diluted through aqueous solutions rather than build it up like enough osmotic pressure within core.

Through order, to retard a dissolution rate like non-pariel seedlings at first absolutely covered as for 2% (w/w) Hydroxy propyl methyl cellulose E5 like a seal wrap [5].

Coating Procedure of Immediate Release Pellets

Sludge like Almotriptan hydrobromide with 6% Croscarmellose sodium, 1% povidone K-30 (w/w) but rather add 0.01% tween 80 have been disintegrated through 100ml acetone. A seal coated fructose pellets (Non-pariel seeds) (#22/#24) have been preheated to almost 35^{o}C as for delicate action in such a pan hard coat, thereafter started spraying fully ready sludge covering % weight build it up 30% w/w through fructose pellets whereas sprinkling an opioid solution pan have been permitted of about circulate for around 10 minutes till the initial drug filling did occur [Table 1]. Hardened pellets have been fitted on such a sifter of about eliminate agglomerates, damaged pellets as well as fine powder [6].

Preparation of Coating Solution

Almotriptan Hydrobromide but also Hydroxypropyl Methylcellulose K 100, Ethyl Celluloses but also Eudragit RS 100 have been begun taking through four different assets ratio 1:0.5, 1:1, 1:1.5 and 1:2 have been disintegrated through 1:1 ratio like methanol as well as dichloromethane, Ethanol but also Acetone respectively [7]. Finally, added 0.1% Tween 80 and 0.5% PEG 400. Composition like covering solution has been encoding with C1, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11 as well as C12. Samples were filtered via nylon cotton and brought into sprayer.

Evaluation Studies

Percentage Yield

Well all portions like rapid onset but also controlled drug release Almotriptan hydrobromide pellets able to prepare through pan coating have been analyzed such as percentage yield of pellets [8]. An exact percentage yield of pellets have been measured by using formula given.

$$Percentage \quad yield \quad of \quad pellets = \frac{Practical\ yield\ of\ pellets}{Theoretical\ yield\ of\ pellets} \times 100$$

Particle Size Distribution by Sieve Analysis

Sieve analysis finished through using electric and magnetic sieve shaker (Kavin Scientific Products). 5 sieve analysis i.e. #18, #20, #22, #44 as well as a collector plate have been chosen to take, thoroughly dried inside a furnace for free of humidity [9]. The common particle sizes of pellets have been evaluated through easy sieve analysis technique.

Drug Content Analysis

Drug content like pellets have been ascertained through U.V spectrophotometry, pellets having 40 mg comparable like opioid have been transmitted to 100ml volumetric flask usually contains pH 7.4

Table 1: Composition of Coating Solution

Coating Batches	Drug: Polymer Ratio	Percentage of Coating (%)	Polymers Used
C1	1:0.5	30	HPMC K-100
C2	1:1	31	
C3	1:1.5	32	
C4	1:2	33	
C5	1:0.5	30	Ethyl Cellulose
C6	1:1	31	
C7	1:1.5	32	
C8	1:2	33	
C9	1:0.5	30	Eudragit RS 100
C10	1:1	31	
C11	1:1.5	32	
C12	1:2	33	

Table 2: FTIR Functional Groups

FTIR Spectrum	O-H Stretch	C-C Stretch	C-H Stretch	C=O Stretch
Almotriptan HBr	3464.92	1566.62	834.43	1090.33
HPMC K 100	3654.84	2285.43	2782.61	1678.96
Ethyl Cellulose	3608.06	1590.00	765.22	1872.46
Eudragit Rs 100	3456.87	1234.43	865.24	1678.96

Table 3: % Yield of Pellets and % Drug Content Analysis Data of Prepared Pellets

Formulation Code	% Yield of Pellets	% Drug content Analysis ± SD
Immediate Release	92.5	96.71± 0.6
F1	94.3	93.03 ± 0.7
F2	84.5	92.78 ± 0.4
F3	92.9	94.43 ± 0.2
F4	91.6	96.22 ± 0.4
F5	89.8	90.32 ± 0.5
F6	86.2	98.02 ± 0.6
F7	91.4	93.01 ± 0.5
F8	90.7	90.76 ± 0.8
F9	89.6	94.32 ± 0.9
F10	85.8	95.92 ± 0.7
F11	92.6	94.42 ± 0.6
F12	91.3	96.89 ± 0.8

Each value represents the mean ± standard deviation (n=3)

phosphorus buffers [10]. Ultrasonic treatment has been performed such as 30 mins filtrated via Watmann filter paper. A supernatant has been evaluated through a UV spectrophotometer ever since suitable solubility about 550 nm.

In-vitro Drug Release Study

Almotriptan hydrobromide 40mg equivalent amount of both early release (10mg) as well as controlled drug release (30 mg) pellets have been loaded through '0' size hard gelatin capsule through hand filling capsule equipment (Kavin Scientific Products). The basket rotation speed were adjusted to 100 rpm, 900 ml 0.1N HCl for 2 hrs but also decided to follow through pH 7.4 phosphate buffer for 10 hrs have been choosen to take just like solubilization media, thermostat there as 37 ± 0.5^0C all through the research [11], 1ml specimen like dissolution medium have been forced to withdraw

Table 4: Particle Size Distribution Data of Almotriptan Hydrobromide Pellets

Formulation Code	Nominal mesh Aperture size (μm)	% Wt. of Pellets Retained	Cumulative % of Pellets Retained
Immediate Release	1000	0	0
	850	8	8
	710	85	93
	355	6	99
F1	1000	0	0
	850	9	9
	710	83.5	92.5
	355	7	99.5
F2	1000	0	0
	850	8	8
	710	81	89
	355	9	98
F3	1000	0	0
	850	8	8
	710	87	95
	355	4	99
F4	1000	0	0
	850	8	8
	710	84	92
	355	7	99
F5	1000	0	0
	850	9	9
	710	85	94
	355	5	99
F6	1000	0	0

Continued on next page

Table 4 continued

Formulation Code	Nominal mesh Aperture size (μm)	% Wt. of Pellets Retained	Cumulative % of Pellets Retained
	850	10	10
	710	83.5	93.5
	355	5	98.5
F7	1000	0	0
	850	6	6
	710	85	91
	355	8	99
F8	1000	0	0
	850	8	8
	710	86	94
	355	4	98
F9	1000	0	0
	850	7	7
	710	84	91
	355	7.7	98.7
F10	1000	0	0
	850	7	7
	710	86	93
	355	6	99
F11	1000	0	0
	850	7	7
	710	82	89
	355	8	97
F12	1000	0	0
	850	8	8
	710	87	87
	355	4	99

there as predetermined time like 1 hr to 12 hrs but also tried to replace with clean dissolution medium. A choosen sample has been filtrated via 0.45 μm Whatman filter paper. Samples were determined such as drug concentration through UV-Visible spectrophotometrically (UV – Spectrometer 2060 plus) about as 550 nm. Information acquired first from *in-vitro* dissolution studies have been made subject as kinetic psychotherapy to acquire a command of discharge but also fit best concept [12] [Figure 8].

RESULTS AND DISCUSSION

Compatibility Studies

Drug Polymer Compatibility

Such research seems to be very necessary in order to substantiate an opioid configuration, its activity, degradation rate as well as discharge sequence of different polymer materials used for the composition [Table 2]. Within present research, this has been noticed that, there have been no major shifts inside its individual major peak value [Figure 1, Figure 2, Figure 3, Figure 4, Figure 5, Figure 6 and Figure 7].



Figure 1: FTIR Spectra of Almotriptan Hydrobromide



Figure 2: FTIR Spectra of HPMC K 100

Evaluation Studies

Percentage Yield of Pellets

The percentage yields like Almotriptan hydrobromide pellets have been estimated. The percentage yields like Almotriptan hydrobromide pellets like



Figure 3: FTIR Spectra of Almotripton + HPMC K 100



Figure 4: FTIR Spectra of Ethylcellulose



Figure 5: FTIR Spectra of Almotriptan + Ethylcellulose



Figure 6: FTIR Spectra of Eudragit RS 100



Figure 7: FTIR Spectra of Almotriptan + Eudragit RS 100



Figure 8: *In-vitro* Drug Release Profiles of Formulations F1-F12

early release has been found to also be 93.6% but also controlled release preparations F1 to F12 has been did find to also be inside the range like 84.51% to 94.97% were seen in Table 3.

Drug Content Analysis

Percentage drug concentration like Almotriptan hydrobromide pellets like instantaneous as well as F1-F12 among all preparations have been ascertained through UV spectrophotometric technique. 3 trials out of each composition have been examined. An average value well as deviation among all preparations have been estimated. A drug content analyze like release pellets has been found to have been in the range like 97.69± 0.8 % and also for controlled drug release preparations F1 to F12 has been found to be there in the range like 90.14 ± 0.7 % to 99.90 ± 0.6 % [Table 3].

Sieve Analysis Method

A particle size distribution have been carried out for both Immediate release and controlled release pellets from F1-F12 Formulations implies the majority of pellets 81-87% falls through a size range like 850-710 μm (# 20/22) mesh fraction i.e., 20 pass but also 22 acquired. A yield like # 20/22 mesh fraction have been found as good. 5-10% pellets have been recognized through the range of 1000-850 μm (#18/20) i.e., 18 pass but also 20 remained. 4-8 % pellets has been recognized within size-range like 710-355 μm (#22/44) i.e., 22 pass as well as 44 remained.1-2% pellets were found fines [Table 4]. Graphs were plotted against Cumulative % of pellets retained and Sieve apertures Size (μm).

CONCLUSION

In present investigation, an attempt has been made to Formulate and Evaluate Almotriptan Hydrobromide Pellets by using HPMC K 100, Ethyl cellulose and Eudragit RS 100 in different ratios as release retarding nature polymers by solution/ Suspension layer technique, which also will lengthen a release of drug resulting in mitigate the height as well as basin impact within blood as well as provide client efficiency suitability of an Almotriptan, polymeric materials but also emigrants was resolute through FTIR spectrometry results revealed that its Almotriptan is suitable as for all Polymeric materials. The whole twelve compositions through the usually F1-F12 contains hydroxypropyl methylcellulose K 100, Ethyl cellulose but also Eudragit RS 100 through 4 numerous ratio analysis (drug: polymer) 1:0.5, 1:1, 1:1.5 and 1:2 was ready. It was conclusively proved just after *in-vitro* Dissolution study between 12 preparations through the F1-F12, combined effect like Almotriptan as well as Eudragit RS 100 F12 composition ratios 1:2 that shown better outcome as 12 hours.

ACKNOWLEDGEMENT

I would like to thank my esteemed Principal (Dr. Venkata Gopala Krishna Sunku), Vasavi Institute of Pharmaceutical Sciences, Vasavi Nagar, Peddapalli (V), Sidhout (M), Kadapa (Dist), Andhra Pradesh, 516247, India.

Conflict of Interest

The authors declare no conflict of interest, financial or otherwise.

Funding Support

The authors declare that they have no funding for this study.

REFERENCES

[1] Ramesh Y, Rohan AK, Koorapati B, et al. Formulation and evaluation of almotriptan controlled release pellets. Journal of Drug Delivery and Therapeutics. 2019;9(1-s):312–318.

[2] Sandrini G, Perrotta A, Leal NLA, et al. Almotriptan in the treatment of migraine. Neuropsychiatric Disease and Treatment. 2007;3(6):799.

[3] Bou J, Domènech T, Puig J, et al. Pharmacologi-

cal characterization of almotriptan: an indolic 5-HT receptor agonist for the treatment of migraine. European journal of pharmacology. 2000;410(1):33–41.

[4] Bou J, Gras J, Cortijo J, et al. Vascular effects of the new anti-migraine agent almotriptan on human cranial and peripheral arteries. Cephalalgia. 2001;21(8):804–812.

[5] Gras J, Llenas J, Jansat JM, et al. Almotriptan, a new anti-migraine agent: A review. CNS drug reviews. 2002;8(3):217–234.

[6] Chen LC, Ashcroft DM. Meta-analysis examining the efficacy and safety of almotriptan in the acute treatment of migraine. Headache: The Journal of Head and Face Pain. 2007; 47(8):1169–1177.

[7] Mathew NT, Finlayson G, Smith TR, et al. Early intervention with almotriptan: results of the AEGIS trial (AXERT® Early Migraine Intervention Study). Headache: The Journal of Head and Face Pain. 2007;47(2):189–198.

[8] Jansat JM, et al. Effect of food intake on the bioavailability of almotriptan, an antimigraine compound, in healthy volunteers: an open, randomized, crossover, single-dose clinical trial. International Journal of Clinical Pharmacology & Therapeutics. 2006;44(4).

[9] Jansat JM, Costa J, Salvà P, et al. Absolute bioavailability, pharmacokinetics, and urinary excretion of the novel antimigraine agent almotriptan in healthy male volunteers. The Journal of Clinical Pharmacology. 2002; 42(12):1303–1310.

[10] Fleishaker JC, et al. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia. 2001; 21(1):61–65.

[11] Fleishaker JC, et al. Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans. British journal of clinical pharmacology. 2001;51(5):437.

[12] Nair AB, Al-Dhubiab BE, Shah J, et al. Mucoadhesive buccal film of almotriptan improved therapeutic delivery in rabbit model. Saudi pharmaceutical journal. 2020;28(2):201–209.

Cite this article: Syed Afzal Hussain, Hari Kumar C, Pradeep Kumar M, Satrasala Neelima. **Formulation and Evaluation of Almotriptan Hydrobromide Pellets**. Int. J.Exp. Biomed. Res. 2022; 1(3): 95-102.